关键词：何杰金氏淋巴瘤；淋巴组织；癌症；削弱；免疫系统
摘 要：Hodgkin's lymphoma is a cancer of the lymph tissue. The exact etiology of Hodgkin's lymphoma is unknown. However, the risk of developing the condition increases if a person suffers from a medical condition that weakens the immune system. In Hodgkin's lymphoma, cells in the lymphatic system grow unusually and may spread beyond the lymphatic system. The infectionfighting properties of the lymphocytes are lost, making the person more susceptible to the infection. Chemotherapy is the main treatment used for treating the condition, followed by radiotherapy.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Classification of Hodgkin's Lymphoma by

the WHO

08. Stages of Hodgkin's Lymphoma

09. Chemotherapy Options for Hodgkin’s

Lymphoma

10. Market Segmentation by Drug Class .

11. Geographical Segmentation

12. Rate of Incidence and Prevalence

12.1.1 US

12.1.2 UK

13. Pipeline Snapshot

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Market Share Analysis 2013

21.3 Other Prominent Vendors

22. Key Vendor Analysis

22.1 Bristol-Myers Squibb

22.1.1 Key Facts

22.1.2 Business Overview

22.1.3 Product Segmentation

22.1.4 Geographical Segmentation by Revenue

22.1.5 Business Strategy

22.1.6 Key Information

22.1.7 SWOT Analysis

22.1.8 Strengths

22.1.9 Weaknesses

22.1.10 Opportunities

22.1.11 Threats

22.2 F. Hoffmann-La Roche

22.2.1 Key Facts

22.2.2 Business Overview

22.2.3 Business Segmentation

22.2.4 Business Segmentation by Revenue 2012 and 2013

22.2.5 Geographical Segmentation by Revenue

22.2.6 Business Strategy

22.2.7 Key Information

22.2.8 SWOT Analysis

22.2.9 Strengths

22.2.10 Weaknesses

22.2.11 Opportunities

22.2.12 Threats

22.3 Merck

22.3.1 Key Facts

22.3.2 Business Overview

22.3.3 Business Segmentation by Revenue 2013

22.3.4 Business Segmentation by Revenue 2012 and 2013

22.3.5 Geographical Segmentation by Revenue

22.3.6 Business Strategy

22.3.7 Key Developments

22.3.8 SWOT Analysis

22.3.9 Strengths

22.3.10 Weaknesses

22.3.11 Opportunities

22.3.12 Threats

22.4 Pfizer

22.4.1 Key Facts

22.4.2 Business Overview

22.4.3 Business Segmentation by Revenue 2013

22.4.4 Business Segmentation by Revenue 2012 and 2013

22.4.5 Geographical Segmentation by Revenue

22.4.6 Business Strategy

22.4.7 Key Developments

22.4.8 SWOT Analysis

22.4.9 Strengths

22.4.10 Weaknesses

22.4.11 Opportunities

22.4.12 Threats

23. Other Reports in this Series